ClinicalTrials.gg
CompletedNCT02493452IBS-CUpdated Jun 14, 2019Results posted

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

A Phase 3 interventional study of Plecanatide and Placebo in Irritable Bowel Syndrome Characterized by Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 191 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-14.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,135
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
4th of 12
1,135 · median 800
Started
2015
the only one that year
Phase 3
6 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 8th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.

Read the detailed description

This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.

Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow for any necessary diagnostic procedures, allow for required washout of medications and to determine study eligibility. If otherwise eligible based on screening criteria, patients will undergo a 2-week baseline assessment using an electronic diary where they will record daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS), abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary assessment just prior to the randomization visit will be used to confirm IBS-C and study eligibility as well as define the patient's baseline from which change will be determined.

Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments.

Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily electronic diaries. Patients will then return to the clinical site for a final follow-up visit during Week 14 following randomization.

The planned duration of participation in this study will be at least 116 days from signing of informed consent through post-treatment or up to approximately 135 days with visit windows considered.

03

Conditions studied

  • Irritable Bowel Syndrome Characterized by Constipation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to sign for the trial
  • Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires
  • ≥ 40 or \< 18
  • Women of child bearing potential who refuse to use an acceptable method of for the duration of the trial
  • Women who are pregnant or lactating
  • Diagnosis of IBS-D or IBS-M
  • Organic or obstructive disease of the small or large intestine
  • Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)
  • Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication
  • Unstable medical illness
  • > 3X in the absence of a conjugation defect
  • Any laboratory value > 3X ULN unless discussed and approved by the study Medical Monitor
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,135 participants (actual)

Study arms

  • Active comparator
    3.0 mg plecanatide

    Plecanatide 3.0 mg dosed daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    6.0 mg plecanatide

    Plecanatide 6.0 mg dosed daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    Matching placebo

    Placebo dosed daily for 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Overall Responders - ITT Population

    An Overall Responder was a patient who was a weekly responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least 1 complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.

    Time frame: 12 weeks

  2. Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks

    An Abdominal Pain Intensity Responder was a patient who had a decrease of 30 % from baseline for abdominal pain intensity. Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: 12 Weeks

  3. Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks

    A Stool Frequency Responder was a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: 12 Weeks

Secondary outcomes

  1. Number of Sustained Efficacy Responders

    A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.

    Time frame: 12 Weeks

  2. Change From Baseline in Stool Consistency

    Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS). Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid

    Time frame: Baseline and 12-Week

  3. Change From Baseline in Straining

    Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).

    Time frame: Baseline and 12-Week

  4. Change From Baseline in CSBMs (CSBMs/Week)Complete Spontaneous Bowel Movement

    Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: Baseline and 12-Week

  5. Number of Patients With a SBM Within 24 Hours After First Dose of Study Medication

    A responder was any patient with a SBM within 24 hours after the first dose of study drug.

    Time frame: Up to 24 hours after the first dose of study drug

  6. Change From Baseline in Abdominal Pain

    Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (None) to 10 (Worst Possible). Baseline was the mean of the non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The average daily abdominal pain score was the average of the non-missing worst daily abdominal pain scores (on a 0 to 10 scale) in the given week.

    Time frame: Baseline and 12-Week

07

Results

Posted Jun 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Started379377379
Completed329328325
Not completed504954

Outcome measures

PrimaryNumber of Overall Responders - ITT Population

An Overall Responder was a patient who was a weekly responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least 1 complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Overall Responders - ITT Population
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Overall Responders - ITT Population548191
PrimaryNumber of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks

An Abdominal Pain Intensity Responder was a patient who had a decrease of 30 % from baseline for abdominal pain intensity. Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks88123129
PrimaryNumber of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks

A Stool Frequency Responder was a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks106129148
SecondaryNumber of Sustained Efficacy Responders

A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number of Sustained Efficacy Responders
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Sustained Efficacy Responders537890
SecondaryChange From Baseline in Stool Consistency

Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS). Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid

Time frame:
Baseline and 12-Week
Reported as:
Mean · score on a scale
Change From Baseline in Stool Consistency
score on a scaleMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline1.99 ± 1.0291.91 ± 0.9021.86 ± 0.912
Week 12 change from baseline1.04 ± 1.5791.55 ± 1.6311.45 ± 1.621
SecondaryChange From Baseline in Straining

Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).

Time frame:
Baseline and 12-Week
Reported as:
Mean · score on a scale
Change From Baseline in Straining
score on a scaleMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline6.75 ± 1.8486.84 ± 1.8606.87 ± 1.920
Week 12 change from baseline-1.66 ± 2.149-2.35 ± 2.540-2.35 ± 2.556
SecondaryChange From Baseline in CSBMs (CSBMs/Week)Complete Spontaneous Bowel Movement

Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
Baseline and 12-Week
Reported as:
Mean · CSBMs per week
Change From Baseline in CSBMs (CSBMs/Week)Complete Spontaneous Bowel Movement
CSBMs per weekMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline0.24 ± 0.4650.26 ± 0.5300.27 ± 0.527
Week 12 change from baseline0.80 ± 1.7791.23 ± 2.3031.63 ± 3.042
SecondaryNumber of Patients With a SBM Within 24 Hours After First Dose of Study Medication

A responder was any patient with a SBM within 24 hours after the first dose of study drug.

Time frame:
Up to 24 hours after the first dose of study drug
Reported as:
Count of participants · Participants
Number of Patients With a SBM Within 24 Hours After First Dose of Study Medication
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Patients With a SBM Within 24 Hours After First Dose of Study Medication119157167
SecondaryChange From Baseline in Abdominal Pain

Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (None) to 10 (Worst Possible). Baseline was the mean of the non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The average daily abdominal pain score was the average of the non-missing worst daily abdominal pain scores (on a 0 to 10 scale) in the given week.

Time frame:
Baseline and 12-Week
Reported as:
Mean · score on a scale
Change From Baseline in Abdominal Pain
score on a scaleMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline6.40 ± 1.6246.56 ± 1.6346.48 ± 1.714
Week 12 change from baseline-1.42 ± 2.116-2.00 ± 2.226-1.87 ± 2.297

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Matching Placebo—1/376 (0.3%)13/376 (3.5%)
3.0 mg Plecanatide—2/375 (0.5%)21/375 (5.6%)
6.0 mg Plecanatide—3/379 (0.8%)22/379 (5.8%)
Most frequent serious events
Most frequent serious events
EventMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Viral infectionInfections and infestations0/3761/3750/379
AsthmaRespiratory, thoracic and mediastinal disorders0/3761/3750/379
Cartilage injuryInjury, poisoning and procedural complications1/3760/3750/379
LFT abnormalInvestigations0/3760/3751/379
CostochondritisMusculoskeletal and connective tissue disorders0/3760/3751/379
Suicidal ideationPsychiatric disorders0/3760/3751/379
Most frequent other events
Most frequent other events
EventMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
DiarrheaGastrointestinal disorders5/37612/37514/379
HeadacheNervous system disorders8/3769/3758/379

Baseline characteristics

Age, Continuous
Age, Continuous(years)Matching Placebo3.0 mg Plecanatide6.0 mg PlecanatideTotal
Mean44.8 ± 14.6844.0 ± 14.6143.1 ± 14.2044.0 ± 14.50
Sex: Female, Male
Sex: Female, Male(Participants)Matching Placebo3.0 mg Plecanatide6.0 mg PlecanatideTotal
Female272270273815
Male107107106320
08

Study locations

191 sites
  • Synergy Research Site
    Birmingham, Alabama 35209, United States
  • Synergy Research Site
    Birmingham, Alabama 35216, United States
  • Synergy Research Site
    Guntersville, Alabama 35976, United States
  • Synergy Research Site
    Huntsville, Alabama 35801, United States
  • Synergy Research Site
    Saraland, Alabama 36571, United States
  • Synergy Research Site
    Glendale, Arizona 85301, United States
  • Synergy Research Site
    Phoenix, Arizona 85018, United States
  • Synergy Research Site
    Surprise, Arizona 85374, United States
  • Synergy Research Site
    Tucson, Arizona 85745, United States
  • Synergy Research Site
    Conway, Arkansas 72034, United States
  • Synergy Research Site
    Little Rock, Arkansas 72205, United States
  • Synergy Research Site
    Canoga Park, California 91303, United States
  • Synergy Research Site
    Carmichael, California 95608, United States
  • Synergy Research Site
    Chino, California 91710, United States
  • Synergy Research Site
    Chula Vista, California 91910, United States
  • Synergy Research Site
    El Cajon, California 92020, United States
  • Synergy Research Site
    Encino, California 91436, United States
  • Synergy Research Site
    Foothill Ranch, California 92610, United States
  • Synergy Research Site
    Garden Grove, California 92844, United States
  • Synergy Research Site
    Huntington Beach, California 92647, United States
  • Synergy Research Site
    Irvine, California 92614, United States
  • Synergy Research Site
    Lomita, California 90717, United States
  • Synergy Research Site
    Long Beach, California 90806, United States
  • Synergy Research Site
    Los Angeles, California 90045, United States
  • Synergy Research Site
    Mission Hills, California 91345, United States
  • Synergy Research Site
    Montclair, California 91763, United States
  • Synergy Research Site
    Northridge, California 91324, United States
  • Synergy Research Site
    Norwalk, California 90650, United States
  • Synergy Research Site
    Oceanside, California 92056, United States
  • Synergy Research Site
    Orangevale, California 95662, United States
  • Synergy Research Site
    Orange, California 92868, United States
  • Synergy Research Site
    Placentia, California 92870, United States
  • Synergy Research Site
    Riverside, California 92501, United States
  • Synergy Research Site
    San Diego, California 92103, United States
  • Synergy Research Site
    San Marino, California 91108, United States
  • Synergy Research Site
    Santa Ana, California, United States
  • Synergy Research Site
    Sherman Oaks, California 91403, United States
  • Synergy Research Site
    Colorado Springs, Colorado 80920, United States
  • Synergy Research Site
    Denver, Colorado 80246, United States
  • Synergy Research Site
    Hamden, Connecticut 06517, United States
  • Synergy Research Site
    Atlantis, Florida 33462, United States
  • Synergy Research Site
    Boca Raton, Florida 33428, United States
  • Synergy Research Site
    Bradenton, Florida 34201, United States
  • Synergy Research Site
    Brandon, Florida 33511, United States
  • Synergy Research Site
    Brooksville, Florida 34601, United States
  • Synergy Research Site
    Clearwater, Florida 33756, United States
  • Synergy Research Site
    Cutler Bay, Florida 33189, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33306, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33312, United States
  • Synergy Research Site
    Hialeah, Florida 33012, United States
  • Synergy Research Site
    Hialeah, Florida 33013, United States
  • Synergy Research Site
    Hialeah, Florida 33016, United States
  • Synergy Research Site.
    Jacksonville, Florida 32256, United States
  • Synergy Research Site
    Lauderdale Lakes, Florida 33319, United States
  • Synergy Research Site
    Maitland, Florida 32751, United States
  • Synergy Research Site
    Miami Lakes, Florida 33016, United States
  • Synergy Research Site
    Miami Lakes, Florida 33173, United States
  • Synergy Research Site
    Miami Springs, Florida 33166, United States
  • Synergy Research Site
    Miami, Florida 33015, United States
  • Synergy Research Site
    Miami, Florida 33016, United States
  • Synergy Research Site
    Miami, Florida 33032, United States
  • Synergy Research Site
    Miami, Florida 33122, United States
  • Synergy Research Site
    Miami, Florida 33126, United States
  • Synergy Research Site
    Miami, Florida 33136, United States
  • Synergy Research Site
    Miami, Florida 33144, United States
  • Synergy Research Site
    Miami, Florida 33155, United States
  • Synergy Research Site
    Miami, Florida 33165, United States
  • Synergy Research Site
    Miami, Florida 33173, United States
  • Synergy Research Site
    Miami, Florida 33176, United States
  • Synergy Research Site
    Miami, Florida 33183, United States
  • Synergy Research Site
    Naples, Florida 34102, United States
  • Synergy Research Site
    North Miami Beach, Florida 33162, United States
  • Synergy Research Site
    Orange Park, Florida 32073, United States
  • Synergy Research Site.
    Orlando, Florida 32806, United States
  • Synergy Research Site
    Orlando, Florida 32807, United States
  • Synergy Research Site
    Ormond Beach, Florida 32174, United States
  • Synergy Research Site
    Pembroke Pines, Florida 33024, United States
  • Synergy Research Site
    Pinellas Park, Florida 33782, United States
  • Synergy Research Site
    Port Orange, Florida 32127, United States
  • Synergy Research Site
    Tamarac, Florida 33319, United States
  • Synergy Research Site
    Tampa, Florida 33613, United States
  • Synergy Research Site
    Tampa, Florida 33634, United States
  • Synergy Research Site
    Williston, Florida 32696, United States
  • Synergy Research Site
    Atlanta, Georgia 30322, United States
  • Synergy Research Site
    Atlanta, Georgia 30342, United States
  • Synergy Research Site
    Decatur, Georgia 30033, United States
  • Synergy Research Site
    Lilburn, Georgia 30047, United States
  • Synergy Research Site
    Marietta, Georgia 30060, United States
  • Synergy Research Site
    Snellville, Georgia 30078, United States
  • Synergy Research Site
    Blackfoot, Idaho 83221, United States
  • Synergy Research Site
    Boise, Idaho 83709, United States
  • Synergy Research Site
    Meridian, Idaho 83646, United States
  • Synergy Research Site
    Blue Island, Illinois 60406, United States
  • Synergy Research Site
    Chicago, Illinois 60602, United States
  • Synergy Research Site
    Evanston, Illinois 60201, United States
  • Synergy Research Site
    Hoffman Estates, Illinois 60169, United States
  • Synergy Research Site
    Morton, Illinois 61550, United States
  • Synergy Research Site
    Oak Lawn, Illinois 60453, United States
  • Synergy Research Site
    Schaumburg, Illinois 60194, United States
  • Synergy Research Site
    Brownsburg, Indiana 46112, United States

Showing the first 100 of 191 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Menees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10. PubMed 32660770 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Nov 2016 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2015
First posted
Jul 9, 2015
Start
Jun 2015
Primary completionActual
Nov 2016
CompletionActual
Feb 2017
Results first posted
Jun 14, 2019
Last update
Jun 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02493452
Responsible party
Sponsor
First posted
Jul 9, 2015
Start date
Jun 2015
Primary completion
Nov 2016
Completion
Feb 2017
Results posted
Jun 14, 2019
Last update
Jun 14, 2019

Study contacts

Paul F.C. Eng, PhD
study director · Synergy Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion